CW Stock Analysis: Curtiss-Wright | NYSE
Aerospace & Defense | NYSE, USA | Market Cap: 25.442m USD | 12M Return: 41.2% | US2315611010 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 175M
EPS Trend: 99.8%
Qual. Beats: 0
Rev. Trend: 99.7%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Curtiss-Wright Corporation (NYSE: CW) is a U.S.-based industrial company that designs and manufactures engineered products, systems, and services primarily for the aerospace & defense, commercial nuclear power, process, and general industrial markets. The company is organized into three segments: Aerospace & Industrial (sensors, actuation components, power management electronics, and surface treatment services such as shot and laser peening); Defense Electronics (embedded computing modules, flight test instrumentation, tactical communications, avionics, and weapons handling systems); and Naval & Power (naval nuclear propulsion equipment, pumps, turbines, valves, arresting gear for naval aviation, and ship repair services for the U.S. Navy). Curtiss-Wright was incorporated in 1929 and is headquartered in Davidson, North Carolina.
The business model is largely B2B, supplying mission-critical components and subsystems to OEMs, government agencies, and military end-users rather than finished consumer goods. A distinguishing feature is its dual exposure to defense and commercial nuclear power generation-two long-cycle, highly regulated end markets that tend to produce stable, multi-year revenue visibility relative to the broader Industrials sector.
- Naval backlog grows on rising U.S. Navy shipbuilding and submarine spending
- Commercial nuclear demand lifts as new reactor projects receive approval
- Bolt-on M&A accelerates defense electronics and aerospace segment growth
| Net Income: 541.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 1.77 > 1.0 |
| NWC/Revenue: 23.00% < 20% (prev 29.44%; Δ -6.44% < -1%) |
| CFO/TA 0.13 > 3% & CFO 721.1m > Net Income 541.2m |
| Net Debt (863.4m) to EBITDA (808.2m): 1.07 < 3 |
| Current Ratio: 1.60 > 1.5 & < 3 |
| Outstanding Shares: last quarter (37.1m) vs 12m ago -1.98% < -2% |
| Gross Margin: 37.73% > 18% (prev 37.34%; Δ 0.39% > 0.5%) |
| Asset Turnover: 68.62% > 50% (prev 63.63%; Δ 4.98% > 0%) |
| Interest Coverage Ratio: 16.27 > 6 (EBIT TTM 688.8m / Interest Expense TTM 42.3m) |
| A: 0.15 (Total Current Assets 2.24b - Total Current Liabilities 1.40b) / Total Assets 5.46b |
| B: 0.84 (Retained Earnings 4.57b / Total Assets 5.46b) |
| C: 0.13 (EBIT TTM 688.8m / Avg Total Assets 5.33b) |
| D: 1.03 (Book Value of Equity 2.77b / Total Liabilities 2.69b) |
| Altman-Z'' = 5.69 = AAA |
| DSRI: 0.94 (Receivables 997.4m/961.6m, Revenue 3.65b/3.31b) |
| GMI: 0.99 (GM 37.34% / 37.73%) |
| AQI: 0.94 (AQ_t 0.48 / AQ_t-1 0.51) |
| SGI: 1.11 (Revenue 3.65b / 3.31b) |
| TATA: -0.03 (NI 541.2m - CFO 721.1m) / TA 5.46b) |
| Beneish M = -3.05 (Cap -4..+1) = AA |
As of August 19, 2026, the stock is trading at USD 695.67 with a total of 356,059 shares traded. Over the past week, the price has changed by -1.46%, over one month by -1.88%, over three months by -2.03% and over the past year by +41.15%.
Current recommended Stop Loss: 657.40 (which is 5.5% or 1.3 ATR below the current price).
Curtiss-Wright has received a consensus analysts rating of 4.22. Therefore, it is recommended to buy CW.
- StrongBuy: 5
- Buy: 1
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 806.5 | 15.9% |
P/E Trailing = 49.735
P/E Forward = 28.4091
P/S = 6.963
P/B = 9.2587
P/EG = 1.9966
Revenue TTM = 3.65b USD
EBIT TTM = 688.8m USD
EBITDA TTM = 808.2m USD
Long Term Debt = 757.4m USD (from longTermDebt, last quarter)
Short Term Debt = 200.0m USD (from shortTermDebt, last quarter)
Debt = 1.34b USD (from shortLongTermDebtTotal, last quarter) + Leases 191.6m
Net Debt = 863.4m USD (calculated: Debt 1.34b - CCE 477.1m)
Enterprise Value = 26.3b USD (25.4b + Debt 1.34b - CCE 477.1m)
Interest Coverage Ratio = 16.27 (Ebit TTM 688.8m / Interest Expense TTM 42.3m)
EV/FCF = 42.07x (Enterprise Value 26.3b / FCF TTM 625.3m)
FCF Yield = 2.38% (FCF TTM 625.3m / Enterprise Value 26.3b)
FCF Margin = 17.11% (FCF TTM 625.3m / Revenue TTM 3.65b)
Net Margin = 14.81% (Net Income TTM 541.2m / Revenue TTM 3.65b)
Gross Margin = 37.73% ((Revenue TTM 3.65b - Cost of Revenue TTM 2.28b) / Revenue TTM)
Gross Margin QoQ = 39.40% (prev 36.28%)
Tobins Q-Ratio = 4.82 (Enterprise Value 26.3b / Total Assets 5.46b)
Interest Expense / Debt = 3.16% (Interest Expense 42.3m / Debt 1.34b)
Taxrate = 21.59% (149.0m / 690.2m)
NOPAT = 540.1m (EBIT 688.8m * (1 - 21.59%))
Current Ratio = 1.60 (Total Current Assets 2.24b / Total Current Liabilities 1.40b)
Debt / Equity = 0.48 (Debt 1.34b / totalStockholderEquity, last quarter 2.77b)
Debt / EBITDA = 1.07 (Net Debt 863.4m / EBITDA 808.2m)
Debt / FCF = 1.38 (Net Debt 863.4m / FCF TTM 625.3m)
Total Stockholder Equity = 2.62b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.16% (Net Income 541.2m / Total Assets 5.46b)
RoE = 20.69% (Net Income TTM 541.2m / Total Stockholder Equity 2.62b)
RoCE = 20.42% (EBIT 688.8m / Capital Employed (Equity 2.62b + L.T.Debt 757.4m))
RoIC = 13.25% (NOPAT 540.1m / Invested Capital 4.08b)
WACC = 10.58% (E(25.4b)/V(26.8b) * Re(11.01%) + D(1.34b)/V(26.8b) * Rd(3.16%) * (1-Tc(0.22)))
Discount Rate = 11.01% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -95.16 | Cagr: -1.53%
[DCF] Terminal Value 71.10% ; FCFF base≈576.5m ; Y1≈660.9m ; Y5≈972.7m
[DCF] Fair Price = 260.7 (EV 10.5b - Net Debt 863.4m = Equity 9.63b / Shares 36.9m; r=10.58% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 99.79 | EPS CAGR: 18.44% | SUE: 0.78 | # QB: 0
Revenue Correlation: 99.74 | Revenue CAGR: 10.37% | SUE: -0.14 | # QB: 0
EPS current Quarter (2026-09-30): EPS=3.75 | Chg30d=-1.82% | Revisions=-29% | Analysts=6
EPS current Year (2026-12-31): EPS=15.29 | Chg30d=+0.47% | Revisions=+29% | GrowthEPS=+15.6% | GrowthRev=+8.6%
EPS next Year (2027-12-31): EPS=17.13 | Chg30d=+0.33% | Revisions=+50% | GrowthEPS=+12.0% | GrowthRev=+8.2%
[Analyst] Revisions Ratio: +21% (up=7, down=4)